Google
MNKD Stock Analysis — MANNKIND CORP (Healthcare >> Biotechnology)
MNKD FAQ
What is MNKD's P/E ratio?
MANNKIND CORP (MNKD) currently trades at a P/E ratio of 146.75.
What is MNKD's ROE?
MANNKIND CORP reports a Return on Equity (ROE) of 40.40%.
What is MNKD's dividend yield?
MANNKIND CORP offers a dividend yield of 0.00%.
What is MNKD's Quality Score?
Our AI rates MNKD's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MNKD?
Our AI Timing Score for MNKD is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MNKD belong to?
MANNKIND CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
MNKD AI Analysis Summary
Our AI summary for MNKD: MANNKIND CORP (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 146.75, ROE of 40.40%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.91
Price
-0.20
(-4.87%)
Day Change
|
|
|---|
MNKD, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
3053
|
| Magic Formula Rank by ROE |
3053
|
| Magic Formula Rank by ROIC |
3013
|
| Price | 3.91 |
| PBV / Sector |
-21.45 / 5.20
|
| Earning Per Share | -0.07 |
| PE / Sector |
146.75 / 19.97
|
| PEG or PE/Growth / Sector |
-0.91 / 1.22
|
| Average 1M Daily Value |
18.08 M
GREAT
|
| Average 1W Daily Value |
17.34 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:11 |
| Symbol | MNKD |
| Name | MANNKIND CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 308.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,269.79 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Casper Street, Danbury, CT, United States, 06810
Phone: 818 661 5000
Website: https://mannkindcorp.com
Employees: 591
Sector: Healthcare >> Biotechnology
Description: MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap